Acutus Medical analyst ratings
Acutus Medical analyst ratings
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $2.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.55, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/24/2022 | 172.73% | BTIG | $2 → $1.5 | Maintains | Buy |
| 04/27/2022 | 263.64% | BTIG | → $2 | Upgrades | Neutral → Buy |
| 04/14/2022 | 81.82% | Goldman Sachs | $5 → $1 | Maintains | Neutral |
| 01/20/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 01/14/2022 | 445.45% | Canaccord Genuity | $10 → $3 | Downgrades | Buy → Hold |
| 11/12/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/12/2021 | 1718.18% | Canaccord Genuity | $18 → $10 | Maintains | Buy |
| 10/22/2021 | 1718.18% | Goldman Sachs | → $10 | Initiates Coverage On | → Neutral |
| 07/15/2021 | 3172.73% | Canaccord Genuity | $11 → $18 | Upgrades | Hold → Buy |
| 03/19/2021 | 2809.09% | Canaccord Genuity | $30 → $16 | Maintains | Hold |
| 03/19/2021 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/19/2021 | 3354.55% | JP Morgan | → $19 | Downgrades | Overweight → Neutral |
| 01/14/2021 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 08/31/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/31/2020 | 5354.55% | Canaccord Genuity | → $30 | Initiates Coverage On | → Hold |
| 08/31/2020 | 6809.09% | B of A Securities | → $38 | Initiates Coverage On | → Buy |
| 08/31/2020 | 6990.91% | JP Morgan | → $39 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 6 月 24 日 | 172.73% | BTIG | $2 → 1.5 美元 | 维护 | 买 |
| 04/27/2022 | 263.64% | BTIG | → 2 美元 | 升级 | 中性 → 买入 |
| 2022 年 4 月 14 日 | 81.82% | 高盛 | 5 美元 → 1 美元 | 维护 | 中立 |
| 01/20/2022 | — | BTIG | 降级 | 买入 → 中性 | |
| 2022 年 1 月 14 日 | 445.45% | Canaccord Genu | 10 美元 → 3 美元 | 降级 | 买入 → 持有 |
| 11/12/2021 | — | 摩根大通 | 降级 | 中性 → 体重不足 | |
| 11/12/2021 | 1718.18% | Canaccord Genu | 18 美元 → 10 美元 | 维护 | 买 |
| 2021 年 10 月 22 日 | 1718.18% | 高盛 | → 10 美元 | 启动覆盖范围开启 | → 中立 |
| 2021 年 7 月 15 日 | 3172.73% | Canaccord Genu | 11 美元 → 18 美元 | 升级 | 持有 → 买入 |
| 03/19/2021 | 2809.09% | Canaccord Genu | 30 美元 → 16 美元 | 维护 | 保持 |
| 03/19/2021 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 03/19/2021 | 3354.55% | 摩根大通 | → 19 美元 | 降级 | 超重 → 中性 |
| 2021 年 1 月 14 日 | — | B of A 类证券 | 降级 | 买入 → 中性 | |
| 08/31/2020 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 08/31/2020 | 5354.55% | Canaccord Genu | → 30 美元 | 启动覆盖范围开启 | → 按住 |
| 08/31/2020 | 6809.09% | B of A 类证券 | → 38 美元 | 启动覆盖范围开启 | → 购买 |
| 08/31/2020 | 6990.91% | 摩根大通 | → 39 美元 | 启动覆盖范围开启 | → 超重 |
Acutus Medical Questions & Answers
Acutus 医学问题与解答
The latest price target for Acutus Medical (NASDAQ: AFIB) was reported by BTIG on June 24, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 172.73% upside). 9 analyst firms have reported ratings in the last year.
BTIG于2022年6月24日公布了Acutus Medical（纳斯达克股票代码：AFIB）的最新目标股价。该分析公司将目标股价定为1.50美元，预计AFIB将在12个月内升至12个月内（可能上涨172.73％）。去年有9家分析公司公布了评级。
The latest analyst rating for Acutus Medical (NASDAQ: AFIB) was provided by BTIG, and Acutus Medical maintained their buy rating.
BTIG提供了Acutus Medical（纳斯达克股票代码：AFIB）的最新分析师评级，Acutus Medical维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on June 24, 2022 so you should expect the next rating to be made available sometime around June 24, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Acutus Medical的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Acutus Medical的最新评级是在2022年6月24日公布的，因此您应该预计下一个评级将在2023年6月24日左右公布。
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $2.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.55, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Acutus Medical（AFIB）评级维持不变，目标股价为2.00美元至1.50美元。Acutus Medical（AFIB）目前的交易价格为0.55美元，超出了分析师的预期区间。